Published in J Gene Med on July 01, 2004
Mitochondrial imaging in dorsal root ganglion neurons following the application of inducible adenoviral vector expressing two fluorescent proteins. J Neurosci Methods (2008) 0.81
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica (2014) 0.80
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (2010) 3.06
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2007) 2.17
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood (2013) 1.95
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol (2010) 1.90
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res (2005) 1.67
NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood (2004) 1.41
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood (2013) 1.34
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood (2010) 1.28
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood (2004) 1.25
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol (2014) 1.24
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother (2010) 1.21
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol (2002) 1.20
The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood (2007) 1.18
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood (2012) 1.16
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol (2009) 1.07
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS One (2011) 1.05
Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol (2013) 1.01
Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol (2012) 1.00
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol (2012) 0.97
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res (2008) 0.95
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol (2012) 0.93
The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol (2011) 0.93
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leuk Res (2013) 0.93
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol (2012) 0.93
Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res (2007) 0.93
The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity. Stem Cells (2013) 0.93
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood (2011) 0.92
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood (2012) 0.91
Transcription factors involved in the regulation of natural killer cell development and function: an update. Front Immunol (2012) 0.91
Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma (2012) 0.89
Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines. Phytochemistry (2008) 0.88
Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica (2003) 0.87
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol (2014) 0.87
Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis (2008) 0.84
A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. Exp Hematol (2009) 0.84
Linezolid induces ring sideroblasts. Haematologica (2013) 0.84
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. Blood (2009) 0.84
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. Am J Hematol (2013) 0.83
An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica (2006) 0.83
Antifungal and cytotoxic activity of withanolides from Acnistus arborescens. J Nat Prod (2010) 0.82
A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors. Mol Cancer (2011) 0.82
Acute myocarditis induced by hypomethylating agents. J Clin Oncol (2011) 0.81
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica (2009) 0.81
Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leuk Res (2010) 0.80
Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am J Hematol (2013) 0.79
Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res (2013) 0.79
Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leuk Res (2012) 0.79
Induction of leukemia-specific CD8+ cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-alpha. Mol Ther (2005) 0.79
Outcome of older patients with acute myeloid leukemia in first relapse. Am J Hematol (2013) 0.78
Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leuk Res (2012) 0.78
Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur J Haematol (2013) 0.78
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol (2014) 0.77
Repression of the RHOH gene by JunD. Biochem J (2011) 0.77
Activity of ladanein on leukemia cell lines and its occurrence in Marrubium vulgare. Planta Med (2009) 0.76
In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. J Obstet Gynaecol Res (2006) 0.76
Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma. Leuk Lymphoma (2004) 0.76
Methyltransferases in myelodysplastic syndromes: guilty or not guilty? Leuk Res (2008) 0.75
Monocyte chemoattractant protein 1 (MCP-1/CCL2) contributes to thymus atrophy in acute myeloid leukemia. Eur J Immunol (2014) 0.75
TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma. Ann Genet (2002) 0.75
Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitor-like state. J Cell Biochem (2011) 0.75
p16(INK4a) immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood (2002) 0.75
Three new cases of non-Hodgkin lymphoma with t(9;14)(p13;q32). Cancer Genet Cytogenet (2003) 0.75
Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells. Cancer Immunol Immunother (2004) 0.75
Chemotherapy increases transgene expression in leukemic cells. J Gene Med (2003) 0.75
Primary central nervous system lymphoma in immunocompetent adults: poor results mainly associated with high treatment related toxicities. Leuk Lymphoma (2002) 0.75
Humulane and germacrane sesquiterpenes from Ferula lycia. J Nat Prod (2010) 0.75
Systemic injection of GM-CSF increases survival in a murine model of acute leukemia. Haematologica (2002) 0.75
Synthesis and biological evaluation of phenstatin metabolites. Bioorg Med Chem (2011) 0.75
Methods for functional analysis of stem cells. Methods Mol Biol (2014) 0.75
RAET1/ULBP alleles and haplotypes among Kolla South American Indians. Hum Immunol (2013) 0.75
Methylation and myelodysplastic syndromes: when and where? Leuk Res (2006) 0.75
Unique effects of mycophenolate mofetil on cord blood T cells: implications for GVHD prophylaxis. Transplantation (2014) 0.75